GRQ,
You say:
"the fact that Virax is one step away from having to call in the administrator."
This is certainly NOT a fact. No one would argue that further funds will be needed after the South African trials. This fact has been reported by the company and I quote from web-site:
"Upon successful completion of the South African trial, VHL will attempt to attract further non-dilutive funding to undertake the Phase II US trial under the open IND with the FDA. The strategy is to partner with a global Pharma at the conclusion of this trial."
The real facts are that Virax has had a successful Phase 11a trial with what I see as exceptionally encouraging results. VIR201 induced an IgG1 immune response against p24
relative to placebo (p=0.018) and also an IgG1 response against gp41
(p=0.066), an antigen not encoded for in VIR201.
I do not understand why you want to down ramp this stock. Yes, there are long term funding issues but that is why VHL has a MC of only approx. $15M. If you want a pharmaceutical company with less risk go away and buy some CSL.
- Forums
- ASX - By Stock
- VHL
- may 1st dndn decision
may 1st dndn decision, page-20
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online